127 related articles for article (PubMed ID: 30036834)
1. Synthesis and biological evaluation of novel larotaxel analogues.
Ren S; Wang Y; Wang J; Gao D; Zhang M; Ding N; Li Y
Eur J Med Chem; 2018 Aug; 156():692-710. PubMed ID: 30036834
[TBL] [Abstract][Full Text] [Related]
2. Larotaxel: broadening the road with new taxanes.
Metzger-Filho O; Moulin C; de Azambuja E; Ahmad A
Expert Opin Investig Drugs; 2009 Aug; 18(8):1183-9. PubMed ID: 19604119
[TBL] [Abstract][Full Text] [Related]
3. Modification of C-seco taxoids through ring tethering and substituent replacement leading to effective agents against tumor drug resistance mediated by βIII-Tubulin and P-glycoprotein (P-gp) overexpressions.
Tang Y; Rodríguez-Salarichs J; Zhao Y; Cai P; Estévez-Gallego J; Balaguer-Pérez F; Redondo Horcajo M; Lucena-Agell D; Barasoain I; Díaz JF; Fang WS
Eur J Med Chem; 2017 Sep; 137():488-503. PubMed ID: 28624703
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and SAR study of Fluorine-containing 3rd-generation taxoids.
Wang C; Chen L; Sun Y; Guo W; Taouil AK; Ojima I
Bioorg Chem; 2022 Feb; 119():105578. PubMed ID: 34979464
[TBL] [Abstract][Full Text] [Related]
5. Novel C2-C3' N-peptide linked macrocyclic taxoids. Part 2: synthesis and biological activities of docetaxel analogues with a peptide side chain at C2 and their macrocyclic derivatives.
Larroque AL; Dubois J; Thoret S; Aubert G; Chiaroni A; Guéritte F; Guénard D
Bioorg Med Chem; 2007 Jan; 15(1):563-74. PubMed ID: 17064914
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of new-generation taxoids.
Ojima I; Chen J; Sun L; Borella CP; Wang T; Miller ML; Lin S; Geng X; Kuznetsova L; Qu C; Gallager D; Zhao X; Zanardi I; Xia S; Horwitz SB; Mallen-St Clair J; Guerriero JL; Bar-Sagi D; Veith JM; Pera P; Bernacki RJ
J Med Chem; 2008 Jun; 51(11):3203-21. PubMed ID: 18465846
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of novel cabazitaxel analogues.
Ren S; Zhang M; Wang Y; Guo J; Wang J; Li Y; Ding N
Bioorg Med Chem; 2021 Jul; 41():116224. PubMed ID: 34058663
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and anticancer activity of novel quinoline-docetaxel analogues.
Chen M; Chen H; Ma J; Liu X; Zhang S
Bioorg Med Chem Lett; 2014 Jul; 24(13):2867-70. PubMed ID: 24835987
[TBL] [Abstract][Full Text] [Related]
9. Novel C2-C3' N-peptide linked macrocyclic taxoids. Part 1: Synthesis and biological activities of docetaxel analogues with a peptide side chain at C3'.
Larroque AL; Dubois J; Thoret S; Aubert G; Guénard D; Guéritte F
Bioorg Med Chem Lett; 2005 Nov; 15(21):4722-6. PubMed ID: 16165352
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of C2-C3'N-linked macrocyclic taxoids. Novel docetaxel analogues with high tubulin activity.
Querolle O; Dubois J; Thoret S; Roussi F; Guéritte F; Guénard D
J Med Chem; 2004 Nov; 47(24):5937-44. PubMed ID: 15537348
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of C-13, C-14 modified taxane analogues from 1-deoxybaccatin VI.
Tang P; Lin HX; Yuan TH; Cui YM
Nat Prod Res; 2019 Dec; 33(24):3478-3484. PubMed ID: 29897250
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and structure-activity relationships of novel taxane-based multidrug resistance reversal agents.
Ojima I; Borella CP; Wu X; Bounaud PY; Oderda CF; Sturm M; Miller ML; Chakravarty S; Chen J; Huang Q; Pera P; Brooks TA; Baer MR; Bernacki RJ
J Med Chem; 2005 Mar; 48(6):2218-28. PubMed ID: 15771464
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological activity of C-7, C-9 and C-10 modified taxane analogues from 1-deoxybaccatin VI.
Xie C; Cui Y; Li L; Zhang M; Liu H; Lin H
Bioorg Med Chem; 2020 Nov; 28(21):115736. PubMed ID: 33065439
[TBL] [Abstract][Full Text] [Related]
14. Syntheses and biological evaluation of C-3'-N-acyl modified taxane analogues from 1-deoxybaccatin-VI.
Li QF; Lin HX; Cui YM; Xu PP
Eur J Med Chem; 2015 Nov; 104():97-105. PubMed ID: 26448037
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of taxoids with improved cytotoxicity and solubility for use in tumor-specific delivery.
Miller ML; Roller EE; Zhao RY; Leece BA; Ab O; Baloglu E; Goldmacher VS; Chari RV
J Med Chem; 2004 Sep; 47(20):4802-5. PubMed ID: 15369381
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the new generation taxane anticancer agents.
Geney R; Chen J; Ojima I
Med Chem; 2005 Mar; 1(2):125-39. PubMed ID: 16787308
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and SAR study of 3rd-generation taxoids bearing 3-CH
Wang C; Wang X; Sun Y; Taouil AK; Yan S; Botchkina GI; Ojima I
Bioorg Chem; 2020 Jan; 95():103523. PubMed ID: 31911305
[TBL] [Abstract][Full Text] [Related]
18. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological activity of macrocyclic taxane analogues.
Tarrant JG; Cook D; Fairchild C; Kadow JF; Long BH; Rose WC; Vyas D
Bioorg Med Chem Lett; 2004 May; 14(10):2555-8. PubMed ID: 15109650
[TBL] [Abstract][Full Text] [Related]
20. Preclinical profile of cabazitaxel.
Vrignaud P; Semiond D; Benning V; Beys E; Bouchard H; Gupta S
Drug Des Devel Ther; 2014; 8():1851-67. PubMed ID: 25378905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
